lansoprazole has been researched along with Cardiovascular Diseases in 8 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Subjects 18 years or older with osteoarthritis, without gastroduodenal ulcer or erosive esophagitis at baseline endoscopy, and a cardiovascular indication for prophylaxis low-dose (81 or 325 mg) aspirin were prescribed open-label aspirin and blindly randomized to celecoxib 200 mg/day or naproxen 500 mg twice daily plus lansoprazole 30 mg once daily." | 5.12 | Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial. ( Amer, F; Cryer, B; Goldstein, JL; Hunt, B, 2007) |
| "lansoprazole was 0." | 1.91 | Cost-Effectiveness of Vonoprazan Compared With Proton Pump Inhibitors in Patients Taking Low-Dose Aspirin for Secondary Prevention of Cardiovascular Events in Japan. ( Deguchi, H; Fernandez, J; Igarashi, A; Ishii, M; Kawai, T; Suzuki, M; Tsujita, K, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Ishii, M | 1 |
| Kawai, T | 1 |
| Tsujita, K | 1 |
| Igarashi, A | 1 |
| Suzuki, M | 1 |
| Deguchi, H | 1 |
| Fernandez, J | 1 |
| Watanabe, A | 1 |
| Momo, K | 1 |
| Tanaka, K | 1 |
| Uchikura, T | 1 |
| Kiryu, Y | 1 |
| Niiyama, K | 1 |
| Kodaira, N | 1 |
| Matsuzaki, A | 1 |
| Sasaki, T | 1 |
| Ma, Y | 1 |
| Li, S | 1 |
| Yang, H | 1 |
| Zhang, Y | 1 |
| Li, H | 1 |
| Zhou, L | 1 |
| Lin, J | 1 |
| Chen, Y | 1 |
| Hou, Y | 1 |
| Zhang, X | 1 |
| Liu, T | 1 |
| Zhou, X | 1 |
| Wang, Y | 1 |
| Tanus-Santos, JE | 1 |
| Pinheiro, LC | 1 |
| Ghebremariam, YT | 1 |
| LePendu, P | 1 |
| Lee, JC | 1 |
| Erlanson, DA | 1 |
| Slaviero, A | 1 |
| Shah, NH | 1 |
| Leiper, J | 1 |
| Cooke, JP | 1 |
| Park, Y | 1 |
| Jung, JM | 1 |
| Tantry, US | 1 |
| Kim, K | 1 |
| Koh, JS | 1 |
| Park, JR | 1 |
| Hwang, SJ | 1 |
| Kwak, CH | 1 |
| Hwang, JY | 1 |
| Kim, S | 1 |
| Gurbel, PA | 1 |
| Jeong, YH | 1 |
| Adamopoulos, AB | 1 |
| Sakizlis, GN | 1 |
| Nasothimiou, EG | 1 |
| Anastasopoulou, I | 1 |
| Anastasakou, E | 1 |
| Kotsi, P | 1 |
| Karafoulidou, A | 1 |
| Stergiou, GS | 1 |
| Goldstein, JL | 1 |
| Cryer, B | 1 |
| Amer, F | 1 |
| Hunt, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Phase 3 Study to Compare the Efficacy and Safety of Lansoprazole 30 mg QD and Naproxen 500 mg BID Versus Celecoxib 200 mg QD in Risk Reduction of Non Steroidal Anti-Inflammatory-Associated Ulcers in Osteoarthritis Subjects Taki[NCT00175032] | Phase 3 | 1,045 participants (Actual) | Interventional | 2003-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for lansoprazole and Cardiovascular Diseases
| Article | Year |
|---|---|
Pharmacodynamic effects of cilostazol versus clopidogrel in stented patients under proton pump inhibitor co-administration: the ACCEL-PARAZOL study.
Topics: Cardiovascular Diseases; Cilostazol; Clopidogrel; Female; Follow-Up Studies; Humans; Lansoprazole; M | 2014 |
Do proton pump inhibitors attenuate the effect of aspirin on platelet aggregation? A randomized crossover study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Aspirin; Cardiovascular Dis | 2009 |
Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovas | 2007 |
5 other studies available for lansoprazole and Cardiovascular Diseases
| Article | Year |
|---|---|
Cost-Effectiveness of Vonoprazan Compared With Proton Pump Inhibitors in Patients Taking Low-Dose Aspirin for Secondary Prevention of Cardiovascular Events in Japan.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cost-Benefit Analysis; Esomeprazole; Gastrointestinal Hemorr | 2023 |
Identification of the Components of Proton Pump Inhibitors and Potassium-Competitive Acid Blocker That Lead to Cardiovascular Events in Working-Age Individuals: A 12-Month Retrospective Cohort Study Using a Large Claims Database.
Topics: Cardiovascular Diseases; Cytochrome P-450 CYP2C19; Humans; Lansoprazole; Male; Potassium; Proton Pum | 2022 |
Acid suppressants use and risk of atherosclerotic cardiovascular disease in middle-aged and older adults.
Topics: Aged; Antihypertensive Agents; Atherosclerosis; Cardiovascular Diseases; Histamine; Humans; Lansopra | 2022 |
Proton pump inhibitors: New mechanisms of action.
Topics: Cardiovascular Diseases; Cathepsin B; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Endot | 2019 |
Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine.
Topics: Amidohydrolases; Animals; Arginine; Biomarkers; Cardiovascular Diseases; Cells, Cultured; Disease Mo | 2013 |